Sg Americas Securities, LLC Supernus Pharmaceuticals, Inc. Transaction History

Sg Americas Securities, LLC

$27.6 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 12, 2024	BUY	$25.99 - $33.85 $371,111 - $483,344	14,279 Added 377.25%	18,064 $483,000
Q1 2024 May 06, 2024	BUY	$27.11 - $35.17 $102,611 - $133,118	3,785 New	3,785 $129,000
Q3 2023 Oct 13, 2023	BUY	$27.57 - $32.91 $799,502 - $954,357	28,999 New	28,999 $800,000
Q4 2022 Feb 02, 2023	BUY	$31.09 - $37.88 $85,963 - $104,738	2,765 Added 28.39%	12,503 $446,000
Q3 2022 Oct 31, 2022	SELL	$28.79 - $35.41 $1.03 Million - $1.26 Million	-35,680 Reduced 78.56%	9,738 $330,000
Q2 2022 Jul 29, 2022	SELL	$25.33 - $34.25 $306,087 - $413,877	-12,084 Reduced 21.01%	45,418 $1.31 Million
Q1 2022 Apr 29, 2022	SELL	$28.51 - $32.9 $674,888 - $778,808	-23,672 Reduced 29.16%	57,502 $1.86 Million
Q4 2021 Feb 07, 2022	BUY	$26.37 - $34.22 $764,044 - $991,490	28,974 Added 55.51%	81,174 $2.37 Million
Q3 2021 Nov 01, 2021	BUY	$23.54 - $31.39 $982,795 - $1.31 Million	41,750 Added 399.52%	52,200 $1.39 Million
Q2 2021 Aug 12, 2021	BUY	$26.72 - $33.19 $74,067 - $92,002	2,772 Added 36.1%	10,450 $322,000
Q1 2021 May 13, 2021	SELL	$24.15 - $31.45 $13,596 - $17,706	-563 Reduced 6.83%	7,678 $201,000
Q4 2020 Feb 04, 2021	SELL	$17.7 - $25.81 $237,622 - $346,499	-13,425 Reduced 61.96%	8,241 $207,000
Q3 2020 Nov 09, 2020	SELL	$20.2 - $25.05 $662,681 - $821,790	-32,806 Reduced 60.23%	21,666 $452,000
Q2 2020 Jul 20, 2020	BUY	$17.09 - $24.89 $554,536 - $807,630	32,448 Added 147.33%	54,472 $1.29 Million
Q1 2020 Apr 30, 2020	BUY	$14.45 - $24.69 $126,480 - $216,111	8,753 Added 65.96%	22,024 $396,000
Q4 2019 Jan 28, 2020	BUY	$19.93 - $29.13 $43,527 - $63,619	2,184 Added 19.7%	13,271 $315,000
Q3 2019 Nov 04, 2019	SELL	$25.47 - $33.37 $157,863 - $206,827	-6,198 Reduced 35.86%	11,087 $305,000
Q2 2019 Jul 29, 2019	BUY	$29.96 - $38.87 $345,528 - $448,287	11,533 Added 200.5%	17,285 $572,000
Q1 2019 Apr 29, 2019	SELL	$32.77 - $41.99 $2.38 Million - $3.05 Million	-72,633 Reduced 92.66%	5,752 $202,000
Q4 2018 Feb 01, 2019	BUY	$30.84 - $49.51 $1.92 Million - $3.08 Million	62,258 Added 386.05%	78,385 $2.6 Million
Q3 2018 Nov 06, 2018	SELL	$42.7 - $56.55 $28,822 - $38,171	-675 Reduced 4.02%	16,127 $812,000
Q2 2018 Aug 07, 2018	BUY	$44.1 - $59.85 $595,173 - $807,735	13,496 Added 408.23%	16,802 $1.01 Million
Q1 2018 May 03, 2018	SELL	$37.15 - $46.9 $149,268 - $188,444	-4,018 Reduced 54.86%	3,306 $151,000
Q4 2017 Jan 24, 2018	SELL	$36.4 - $42.6 $550,076 - $643,771	-15,112 Reduced 67.36%	7,324 $292,000
Q3 2017 Nov 07, 2017	BUY	$36.75 - $49.65 $824,523 - $1.11 Million	22,436	22,436 $897,000

Others Institutions Holding SUPN

# of Institutions

282

Shares Held

60.9M

Call Options Held

27.7K

Put Options Held

11.3K

Black Rock Inc. New York, NY

10.4M
Shares

$376 Million
0.01% of portfolio
Vanguard Group Inc Valley Forge, PA

6.13M
Shares

$222 Million
0.0% of portfolio
Armistice Capital, LLC New York, NY

5.1M
Shares

$185 Million
2.64% of portfolio
Dimensional Fund Advisors LP Austin, TX

2.88M
Shares

$104 Million
0.02% of portfolio
Macquarie Group LTD Australia, C3

2.63M
Shares

$95.3 Million
0.09% of portfolio

View Full List

About SUPERNUS PHARMACEUTICALS, INC.

Ticker SUPN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 53,495,300
Market Cap $1.94B
Description
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...

More about SUPN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.

Account